Ferrer signs $122M biobucks deal for ex-US license to Verge’s …

Jul 10, 2024 · Ferrer has signed off on over 112.5 million euros ($121.7 million) in combined upfront and potential development and commercial milestone payments for the ex-U.S. rights …

CouponFollow Extension

$122
OFF

Ferrer Signs $122M Biobucks Deal For Ex-US License To Verge’s …

2 days from now

Jul 10, 2024 · Ferrer has signed off on over 112.5 million euros ($121.7 million) in combined upfront and potential development and commercial milestone payments for the ex-U.S. rights …

biotech-insider.com

€122
OFF

Spanish Ferrer SA Pays €122.5m For ALS Candidate

2 days from now

Mar 26, 2024 · Ferrer inked a €112.5m deal with the US-headquartered AI drug discovery specialist Verge Genomics to commercialise the PIKfyve (1 phosphatidylinositol 3 phosphate 5 …

european-biotechnology.com

$122
OFF

Ferrer Signs $122M Biobucks Deal For Ex-US License To Verge's …

2 days from now

Spanish pharma Ferrer is following in Big Pharma’s footsteps by targeting the AI-powered neuroscience R&D work of Verge Genomics. Ferrer has signed...

biotech-now.co.uk

$122
OFF

Ferrer Signs $122M Biobucks Deal For Ex-US License To Verge's …

2 days from now

Jul 10, 2024 · Ferrer has signed off on over 112.5 million euros ($121.7 million) in combined upfront and potential development and commercial milestone payments for the ex-U.S. rights …

biotech-today.com

$122
OFF

VRG-50635 - Drug Targets, Indications, Patents - Synapse - Patsnap

2 days from now

Ferrer signs $122M biobucks deal for ex-US license to Verge's phase 1 ALS therapy. ... (ALS) drug VRG50635. Verge is also entitled to a slice of the royalties should VRG50635 make it to …

patsnap.com

$122
OFF

PIKFYVE - Drugs, Indications, Patents - Synapse - Patsnap

2 days from now

Ferrer signs $122M biobucks deal for ex-US license to Verge's phase 1 ALS therapy. ... (ALS) drug VRG50635. Verge is also entitled to a slice of the royalties should VRG50635 make it to …

patsnap.com

FAQs about Ferrer signs $122M biobucks deal for ex-US license to Verge’s … Coupon?

Is Ferrer launching AI-powered neuroscience R&D work with verge genomics?

Spanish pharma Ferrer is following in Big Pharma’s footsteps by targeting the AI-powered neuroscience R&D work of Verge Genomics. ...

What is verge's collaboration with Ferrer?

The collaboration combines Verge's all-in-human technology for target discovery and drug development and their leadership in clinical trial innovation with Ferrer's global expertise in clinical development, manufacturing, and commercialization. ...

Is PIKfyve a therapeutic target for ALS?

Verge and other top research groups have shown that in ALS, this pathway is dysregulated, leading to neuronal death and disease progression. After the discovery of PIKfyve as a therapeutic target for ALS, Verge developed PIKfyve inhibitors that have been effective in reversing disease-relevant pathology in multiple preclinical models of ALS. ...

Why did Ferrer become a B Corp?

For additional information, please follow us on LinkedIn and Twitter. At Ferrer we use business to fight for social justice and meet the highest standards of social and environmental performance, transparency, and corporate responsibility. That is why in 2022 we became a B Corp company. ...

Will vrg50635 fill an ALS-shaped hole in Ferrer's pipeline?

VRG50635 will fill an ALS-shaped hole in Ferrer’s pipeline that was created in January when the Ferrer’s oral formulation of edaravone—an antioxidant that is sold in a different formulation by Mitsubishi Tanabe Pharma as Radicava— failed a phase 3 trial. ...

What does verge do for ALS?

Verge has further demonstrated the power of CONVERGE™ by delivering a broad pipeline spanning diverse therapeutic areas, with its first program, an investigational PIKfyve inhibitor for the treatment of ALS, now in the clinic. ...